Potential Nutraceutical Properties of Leaves from Several Commonly Cultivated Plants by Amat-ur-Rasool, Hafsa et al.
biomolecules
Article
Potential Nutraceutical Properties of Leaves from
Several Commonly Cultivated Plants
Hafsa Amat-ur-Rasool 1,2 , Fenella Symes 3, David Tooth 4, Larissa-Nele Schaffert 1,
Ekramy Elmorsy 1,5 , Mehboob Ahmed 2 , Shahida Hasnain 2 and Wayne G. Carter 1,*
1 School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby DE22 3DT, UK;
hafsa.phd.mmg@pu.edu.pk (H.A.-u.-R.); mzyls6@exmail.nottingham.ac.uk (L.-N.S.);
ekramyelmorsy@mans.edu.eg (E.E.)
2 Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore 54590, Pakistan;
mehboob.mmg@pu.edu.pk (M.A.); Shahida.mmg@pu.edu.pk (S.H.)
3 School of Pharmacy, University of Nottingham, Nottingham NG7 2UH, UK; fenellasymes@googlemail.com
4 School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK;
David.tooth@nottingham.ac.uk
5 Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Mansoura University,
Mansoura 35516, Egypt
* Correspondence: Wayne.carter@nottingham.ac.uk; Tel.: +44-0-1332-724-738
Received: 15 October 2020; Accepted: 13 November 2020; Published: 15 November 2020 
Abstract: Chronic dietary ingestion of suitable phytochemicals may assist with limiting or
negating neurodegenerative decline. Current therapeutics used to treat Alzheimer disease elicit
broad adverse drug reactions, and alternative sources of cholinesterase inhibitors (ChEIs) are
required. Herein, we screened methanolic extracts from seven commonly cultivated plants for their
nutraceutical potential; ability to inhibit acetylcholinesterase (AChE) and butyryl-cholinesterase
(BuChE), and provision of antioxidant activity through their 2,2-diphenyl-1-picryl-hydrazyl-hydrate
(DPPH) free radical scavenging capabilities. Potential neurotoxicity of plant extracts was examined
via application to SHSY-5Y neuroblastoma cells and quantitation of cell viability. Methanolic extracts
of Citrus limon (Lemon), Bombax ceiba (Red silk-cotton), Lawsonia inermis (Henna), Eucalyptus globulus
(Eucalyptus), Ocimum basilicum (Basil), Citrus reticulata (Mandarin orange), and Mentha spicata
(Spearmint) all displayed concentration-dependent inhibition of AChE and BuChE. The majority of
extracts inhibited AChE and BuChE to near equipotency, with Henna and Eucalyptus extracts the two
most potent ChEIs. All plant extracts were able to scavenge free radicals in a concentration-dependent
manner, with Eucalyptus the most potent antioxidant. Toxicity of plant extracts to neuronal
cells was concentration dependent, with Eucalyptus also the most toxic extract. Fractionation
of plant extracts and analysis by mass spectrometry identified a number of plant polyphenols
that might have contributed to the cholinesterase inhibition: 3-caffeoylquinic acid, methyl
4-caffeoylquinate, kaempferol-acetyl-glycoside, quercetin 3-rutinoside, quercetin-acetyl-glycoside,
kaempferol 3-O-glucoside, and quercetin 3-O-glucoside. In silico molecular modeling of these
polyphenols demonstrated their improved AChE and BuChE binding affinities compared to the
current FDA-approved dual ChEI, galantamine. Collectively, all the plant extracts contained
nutraceutical agents as antioxidants and ChEIs and, therefore, their chronic consumption may prove
beneficial to combat the pathological deficits that accrue in Alzheimer disease.
Keywords: Alzheimer disease; acetylcholinesterase inhibitors; antioxidants; butyrylcholinesterase
inhibitors; molecular modelling; nutraceuticals; phytochemicals
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1. Introduction
Globally, we are living longer and with a demographic shift such that the proportion of the
population over 60 has grown dramatically, estimated to be approximately 1 billion in 2017 but expected
to double by 2050 [1]. As a consequence of population growth, the number of people living with
dementia doubled between 1990 and 2016 to approximately 44 million [2] and the current number of
approximately 50 million sufferers is expected to triple by 2050 [3].
Age itself represents the greatest risk factor for dementia and associated disability-adjusted life
years [4]. Hence, living longer does not guarantee living healthier.
Additionally, there are other risk factors for dementia and Alzheimer disease (AD) including
genetic predispositions [5] and environmental exposures [6], as well as lifestyle factors including
smoking [4], excessive consumption of alcohol [7], and diet, such as levels of dietary fats [8].
The benefits of diets rich in fruits and vegetables as well as a low consumption of alcohol have
been purported to contribute to reduced dementia risk and the health and longevity associated with a
‘Mediterranean lifestyle’ [9–14]. One of the proposed mechanisms responsible for the health benefits of
certain foods and supplements is the provision of natural antioxidants that may balance age-related
oxidative damage and limit the pathological changes associated with neurodegeneration [15–17].
The neuropathic characterization of the major neurodegenerative disease, AD, is via the deposition
of extracellular amyloid plaques of aggregated Aβ, and intracellular neurofibrillary tangles composed
of the microtubule-associated protein (MAP) tau, which becomes extensively post-translationally
modified (hyperphosphorylated) and aggregated within protein deposits [18,19]. These peptide (Aβ)
and protein (tau) aggregates are thought to be toxic and contribute to the loss of neuronal number and
cognitive ability, most notably within the frontotemporal lobes, including the entorhinal cortex and
hippocampal regions of the brain [18,20]. Induction of oxidative stress and neuro-inflammation have
also been proposed to contribute to brain damage in AD [21,22]. The cognitive decline experienced by
AD patients is exacerbated by reduced functionality of the cholinergic pathways [22,23] (Figure 1a).
Cholinergic signaling is mediated by the transport of the neurotransmitter, acetylcholine (ACh),
across the synaptic cleft to initiate post-synaptic transmission at nerves or at the neuromuscular
junction. Acetylcholinesterase (AChE) is tethered to the post-synaptic membrane and is able to rapidly
cleave ACh into acetate and choline and, thereby, terminate ACh stimulation (Figure 1b). The ability
to sustain ACh levels through inhibition of AChE is the current mainstay of treatment for mild to
moderate AD and is the primary mode of action for the FDA-approved drugs: donepezil, rivastigmine,
and galantamine [24,25].
Emerging scientific evidence supports the potential use of dual (acetyl- and butyryl-) cholinesterase
inhibitors (ChEIs) [26]. Indeed, the efficacy of rivastigmine may, in part, relate to its dual inhibitor
ability [24]. The discovery of plant alkaloids as the source of the ChEIs, rivastigmine and galantamine,
has prompted an ongoing search for phytochemicals with anti-cholinesterase activities. Phytochemicals
and plant extracts may also possess a range of secondary metabolites with antioxidant activity and low
target cell toxicity.
To this end, we investigated the nutraceutical potential of leaves from seven commonly cultivated
plants: Lemon (Citrus limon), Red silk-cotton (Bombax ceiba), Henna (Lawsonia inermis), Eucalyptus
(Eucalyptus globulus), Basil (Ocimum basilicum), Mandarin Orange (Citrus reticulata), and Spearmint
(Mentha spicata). These plants were chosen on the basis of their availability, use within folk medicine
(including within Pakistan), and previously reported phytochemicals with potential anti-cholinergic
activity (Supplementary Table S1).
Citrus limon (family Rutaceae) is a small, evergreen tree native to South Asia and grown in regions
with temperate summers. The tree is harvested for production of lemons (edible fruit) and lemon juice
(harnessed for use in the drinks industry), as well as production of essential oils from lemon peel [27].
Plant leaves are also utilized and extoled for their health benefits when consumed as a tea [28].
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Figure 1. The cholinergic system and cholinergic synapse. (a) Overview of the cholinergic system: DB, 
diagonal band of Broca; LDT, laterodorsal pontine tegmentum; MSN, medial septal nucleus; NB, 
nucleus basalis; PPT, pedunculopontine tegmental nucleus. (b) The cholinergic synapse: ACh, 
acetylcholine; AChE, acetylcholinesterase; BuChE, butyrylcholinesterase; ChAT, choline 
acetyltransferase; CHT1, choline transporter; VAChT, vesicular acetylcholine transporter. 
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Figure 1. The cholinergic system and cholinergic synapse. (a) Overview of the cholinergic
system: DB, diagonal band of Broca; LDT, laterodorsal pontine tegmentum; MSN, medial septal
nucleus; NB, nucleus basalis; PPT, pedunculopontine tegmental nucleus. (b) The cholinergic
synapse: ACh, acetylcholine; AChE, acetylcholinesterase; BuChE, butyrylcholinesterase; ChAT, choline
acetyltransferase; C T1, c li e tra s rter; AChT, vesicular acetylcholine transporter.
Bo bax ceiba (family Bombacaceae) is a deciduous tree ocat d within tropical and subtropical
Asia. The flowers and flower buds are used in cooking and the productio of tea, a d othe tre parts
including ro ts and leaves have been utilized in traditional medicines [29,30].
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Lawsonia inermis (family Lythraceae) more commonly known as Henna, is a branched, glaborous
shrub or small tree commonly located within Africa, Asia, and Australia. Henna leaves contain a
broad number of phytochemicals, including lawsome, and have been used historically for temporary
skin staining and as a hair dye. Henna has been cultivated for its leaves, flowers, seeds, stem bark,
and roots, from which extractions have been used in traditional medicine to treat a broad number of
conditions [31–34].
Eucalyptus globulus (family Myrtaceae) is a member of the expansive Eucalyptus genus, native
to Australia, and usually distributed within tropical and subtropical regions. Extracts and essential
oils from the leaves of Eucalyptus plants including E. globulus have been exploited as a traditional
medicine for their beneficial pharmacological activities [35,36].
Ocimum basilicum (family Lamiaceae) is native to Southeast Asia and Africa. It is extensively
cultivated for its leaves, utilized as a culinary herb, and essential oil. Plant seeds and flower buds can
also be harvested for food or added to drinks. O. basilicum (basil) has been utilized for traditional
medicines with plant leaves and seeds rich in polyphenols, such as phenolic acids, with antioxidant
potential [37,38].
Citrus reticulata (family Rutaceae) is another member of the Citrus genus and is believed to be
native to Southeast Asia. C. reticulata is grown and harvested for its edible, soft, citrus fruit and peel
utilized for essential oil and traditional medicines [27].
Mentha spicata (family Lamiaceae) is a gastronomic herb native to Europe and Southern Asia, with
leaves cultivated for use in foods and teas, and utilized as a flavoring and aromatic oil. Plant extracts
have also been traditionally utilized for their medicinal properties throughout the Mediterranean [39].
2. Materials and Methods
2.1. Plant Samples and Chemicals
Acetylcholinesterase (AChE) (EC 3.1.1.7), butyrylcholinesterase (BuChE) (EC 3.1.1.8),
acetylthiocholine iodide (ATCI), 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB), galantamine
hydrobromide (C17H21NO3.HBr; 368.27 g/mol), 2,2-diphenyl-1-picrylhydrazyl (DPPH), α-tocopherol
(Vitamin E), thiazolyl blue tetrazolium bromide (MTT), isopropanol, and dimethyl sulfoxide (DMSO)
were purchased from Sigma Aldrich (Poole, UK). Dulbecco’s Modified Eagle’s Medium (DMEM), fetal
bovine serum albumin (FBS), and poly-d-lysine (PDL) were purchased from Gibco (Loughborough,
UK). Seven plants of purported medicinal benefit were collected from the Quaid-e-Azam Campus,
University of the Punjab, Lahore, and further processed according to botanical standards. Voucher
specimens were deposited in the Herbarium of the Botany Department, Abdul Wali Khan
University, Mardan, Pakistan, to obtain their respective voucher numbers. The plant leaves
studied were from Citrus limon (AWKUM.Bot.132.3.6.p21), Bombax ceiba (AWKUM.Bot.119.1.1.p1),
Lawsonia inermis (AWKUM.Bot.78.3.1.p5), Eucalyptus globulus (AWKUM.Bot.FOC.1.18.p323), Ocimum
basilicum (AWKUM.Bot.192.59.2.p294), Citrus reticulata (AWKUM.Bot.132.3.4.p25), and Mentha spicata
(AWKUM.Bot.192.48.6.p262).
The phenological stages of the plants were as follows: Citrus limon, fruit development; Bombax
ceiba, senescence; Lawsonia inermis, fruit development; Eucalyptus globulus, fruit development; Ocimum
basilicum, flowering; Citrus reticulata, fruit development; and Mentha spicata, flowering.
2.2. Preparation of Plant Extracts
Plant leaves were air-dried and ground to a fine powder using an electric grinder (Cambridge
Food Processor, FP 235, Cambridge Electric Company, Cambridge, UK). Powdered plant material (50 g)
was wrapped in Whatman filter paper and fixed in the extractor glass tube of a Soxhelt apparatus.
Methanol (500 mL) was used as the extraction solvent and poured into the round-bottomed flask of
the apparatus. The apparatus was run at 60 ◦C, with running water used as cooling agent for the
condenser. The plant material-to-solvent ratio was kept as 1:10 (w/v). Extraction was run for five cycles
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for a total of 4 h. Crude extract collected within the round-bottomed flask at the end of extraction was
cooled to room temperature and sieved through Whatman filter paper by funneling into a conical flask.
The volume of methanol solvent was reduced using a Rotary Evaporator (4000 Efficient, Heidolph
Instruments, Schwabach, Germany). The extracts were then freeze-dried (Alpha 2–4 LD Lyophilizer,
Martin Christ, Osterode am Harz, Germany) after adding 50% celite (w/w) (Sigma-Aldrich, Poole, UK)
to generate a fine powder. The extracted (lyophilized) compounds were used for experimentation.
2.3. AChE and BuChE Inhibitory Activity
Measurements of inhibition of AChE or BuChE were determined by a modified Ellman’s
procedure [40], adapted for a 96-well plate. Within each well, 40 µL of 0.01 M DTNB, 46 µL of
0.1 M (pH 8.0) phosphate buffer, 2 µL of 0.075 M substrate, and 10 µL of sample extract were mixed.
The enzymatic reaction was initiated by the addition of 2 µL of 0.5 U/mL AChE or BuChE and then
monitored at 412 nm using a spectrophotometer (Multiskan Spectrum, Thermo Electron Corporation,
Vantaa, Finland). Plant extracts were assayed across a concentration range of 0.16, 0.31, 0.63, 1.25,
and 2.5 mg/mL, and the percentage of inhibition of AChE or BuChE was calculated relative to no
inhibitor controls. All assays were performed in duplicates, with negative controls (no enzyme)
values subtracted from all data points. Galantamine was used as a positive control for inhibition of
either AChE or BuChE. The concentration of plant extract that inhibited 50% of the cholinesterase
activity (IC50) was calculated by nonlinear regression using GraphPad Prism V.7 (San Diego, CA, USA;
https://www.graphpad.com/scientific-software/prism/).
2.4. Antioxidant Activity
Antioxidant activity of the plant extracts was determined using a 2,2-diphenyl-1-picryl-hydrazyl-
hydrate (DPPH) free radical scavenging assay. Plant extracts, over a concentration range of 12.5, 25, 50,
100, and 200 µg/mL, were prepared in 20 µL of methanol and mixed with 180 µL of 0.1 mM DPPH
in 80% (v/v) methanol in a 96-well microtiter plate. The plate was incubated at 37 ◦C for 40 min and
then optical density of the solution was measured at 517 nm using a spectrophotometer (Multiskan
Spectrum, Thermo Electron Corporation), as described in a previous publication [41]. The percentage
DPPH radical scavenging (antioxidant) activity was calculated relative to α-tocopherol (vitamin E)
used as a positive control. All data points were performed in duplicates, with the absorbance values
from negative controls subtracted.
2.5. Cytotoxicity Assays
Human neuroblastoma (SH-SY5Y) cells were purchased from the European Collection of
Authenticated Cell Culture (ECACC) (ECACC-94030304). SH-SY5Y cells were grown in a culture
medium of 43.5% Eagle’s Minimum Essential Medium (EMEM) (M4655, Sigma, Poole, UK)
supplemented with 43.5% Ham’s F12 nut mix (217665-029, Gibco, Waltham, MA, USA), 10%
heat-inactivated fetal bovine serum (FBS) (F9665, Sigma), 1% MEM Non-Essential Amino Acid
Solution (RNBF3937, Sigma), 2 mM glutamine, and 1% penicillin-streptomycin solution containing
10,000 IU penicillium and 10 mg/mL streptomycin (P4333, Sigma) in T25 flasks (130189, Thermofisher
Scientific, Rochester, UK) at 37 ◦C within an atmosphere of 5% CO2 and 95% humidity. SH-SY5Y cells
(passage 15) were seeded in 96-well plates at 3× 104 cells/well and grown until 80–90% confluence before
treatment with plant extracts at 156, 312, 625, 1250, or 2500 µg/mL. After 48 h, cell culture media was
removed and replaced with 0.5% (w/v) thiazolyl blue tetrazolium bromide (MTT) reagent containing
growth media. Plates were incubated at 37 ◦C for 4 h before removal of media and replacement
with 1:1 (v/v) isopropanol:DMSO, and absorbance was recorded at 570 nm using a spectrophotometer
(Multiskan Spectrum, Thermo Electron Corporation). The effect of different concentrations of plant
extracts was determined by comparing the viability of treated cells with untreated control cells, and the
plant concentration able to inhibit cell viability by 50% (IC50) was calculated by nonlinear regression
using GraphPad Prism V.7.
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2.6. Liquid-Chromatography Mass-Spectrometry (LC-MS)
Plant extracts were analyzed using reversed-phase (Phenomenex; Jupiter C18; 4.6 × 250mm, 5 µm
300 Å) (Agilent, Cheshire, UK) high-pressure liquid chromatography with a 5–60% (v/v) gradient of
acetonitrile in 0.1% (v/v) formic acid chromatographed at 1.0 mL.min−1, with 90% of flow directed to a
microplate fraction collector (Dionex; Foxy Jr, Themofisher, Loughborough, UK). Mass spectrometry
(QToF Premier, Waters, UK) was performed in negative ion electrospray mode, with instrument control
and externally calibrated (sodium iodide; similar to 10 ppm), and data processed using MassLynx 4.1
software (Waters, UK).
2.7. In Silico Molecular Docking Studies
The 3D structures of human AChE (PDB ID: 4EY5) and BuChE (PDB ID: 6I0C) enzymes were
downloaded from RCSB-Protein Data Bank (PDB) (https://www.rcsb.org/). The 3D structures of the
potential ChEIs identified by LC-MS/MS were downloaded from the National Center for Biotechnology
Information PubChem database (https://pubchem.ncbi.nlm.nih.gov/). The 3D structures of these
potential ligands were docked with the target enzymes AChE and BuChE separately using AutoDock
Vina software and MGL tools (The Scripps Research Institute, La Jolla, CA, USA) [42]. Molecular
docking results were visually analyzed using PyMOL v2.4. (Schrödinger) and the ligands ranked with
regards to their binding affinities to the target enzymes.
2.8. Statistical Analysis
Statistical analysis was performed using GraphPad Prism V.7. Determination of IC50 values were
obtained by nonlinear regression (inhibitor vs. normalized response-variable slope) based on a best-fit
model from at least four data points. Comparison between groups was performed using a one-way
analysis of variance (ANOVA). A Spearman rank-order correlation coefficient was used to quantify the
relationship between the studied parameters. A p value of below 0.05 was considered significant.
3. Results
3.1. Assessment of Plant Extract AChE and BuChE Inhibitory Activity
Plant extracts were scrutinized across a concentration range of 0.16–2.5 mg/mL for their ability to
inhibit AChE or BuChE using a modified Ellman’s spectrophotometric assay. Plant extracts inhibited
the cholinesterases in a concentration-dependent manner (Figure 2a,b). The actual or extrapolated
concentration able to produce 50% inhibition (IC50) of AChE or BuChE was calculated by nonlinear
regression (Table 1). The anti-cholinesterase drug, galantamine, was used to provide a comparison of
AChE and BuChE inhibitory activity. Galantamine inhibitor-response curves for AChE and BuChE
are included in Figure 2c. From nonlinear regression, IC50 values for galantamine vs. AChE and
BuChE were calculated as 0.19 µg/mL (0.51 µM) and 0.49 µg/mL (1.3 µM), respectively (Supplementary
Figure S1), and are included in Table 1.
Henna (Lawsonia inermis) leaf extract was the most potent plant inhibitor of both AChE and BuChE,
with IC50 values of 0.33 and 0.41 mg/mL, respectively (Table 1). Interestingly, the majority of these plant
extracts were equipotent inhibitors of AChE and BuChE (Figure 3 and Table 1). Galantamine inhibited
AChE and BuChE close to maximal levels, as did the methanolic extract of L. inermis (Figure 3). AChE
inhibitory potency for the plant extracts was in the order L. inermis > E. globulus > C. reticulata > C. limon
> O. basilicum > B. ceiba > M. spicata. BuChE inhibitory potency was similar in order for the first four
extracts: L. inermis > E. globulus > C. reticulata > C. limon > M. spicata > O. basilicum > B. ceiba (Figure 3
and Table 1).
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Figure 2. Assessment of the ability of plant extracts and galantamine to inhibit AChE and BuChE.
(a) Inhibition of AChE by plant extracts. (b) Inhibition of BuChE by plant extracts. (c) Inhibition of
AChE and BuChE by galantamine. Assays were performed using modified Ellman’ assay [40]. Results
are expres ed as means ± SEM, for a n-number of 4.
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Table 1. AChE and BuChE inhibitory capacity, DPPH radical scavenging, and cell viability assessment
(MTT assay) of plant extracts.
Agent Alternative or
Common Name
IC50 (mg/mL) ED50 (µg/mL) IC50 (mg/mL)
AChE BuChE DPPH MTT
Citrus limon Lemon 2.59 ± 0.14 1.82 ± 0.10 839.40 ± 135.2 1.77 ± 0.03
Bombax ceiba Red silk-cotton 6.26 ± 0.72 7.38 ± 0.96 69.69 ± 3.01 1.51 ± 0.08
Lawsonia
inermis Henna 0.33 ± 0.02 0.41 ± 0.02 33.68 ± 1.04 0.58 ± 0.02
Eucalyptus
globulus Eucalyptus 1.11 ± 0.07 0.99 ± 0.05 22.15 ± 1.23 0.40 ± 0.01
Ocimum
basilicum Basil 4.84 ± 0.47 5.90 ± 0.81 56.13 ± 2.01 0.98 ± 0.03
Citrus reticulata Mandarin 1.56 ± 0.20 1.51 ± 0.09 359.30 ± 31.64 0.68 ± 0.03
Mentha spicata Spearmint 10.49 ± 2.06 5.82 ± 0.77 28.94 ± 0.96 1.12 ± 0.03
Galantamine Galanthamine 0.00019 0.00049 ND 3.53 ± 0.21
Vitamin E α-tocopherol ND ND 7.73 ± 0.66 ND
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Figure 3. Comparison of BuChE and AChE inhibitory activity for plant extracts. The ability of
plant extracts at 2.5 mg/mL to inhibit BuChE and AChE was compared with that for galantamine at
0.01 mg/mL. Results are expressed as means ± SEM, for an n-number of 4.
3.2. Assessment of Plant Extract Antioxidant Activity
Intrinsic antioxidant activity for the plant extracts was assessed via the ability to scavenge free
radicals using a DPPH assay. All plant extracts displayed free radical scavenging (antioxidant) ability
that was extract concentration dependent (Figure 4). The antioxidant capacity of the plant extracts
was E. globulus > M. spicata > L. inermis > O. basilicum > B. ceiba, generating similar hyperbolic curves
(Supplementary Figure S2). By comparison, the antioxidant capability was relatively low for the citrus
fruits, C. limon and C. reticulata, and increased linearly with extract concentration (Supplementary
Figure S2). At the higher concentrations examined (50–200 µg/mL), radical scavenging was to a similar
level as the antioxidant vitamin E for several of the extracts (Figure 4). The concentration of extract able
to produce a 50% effect (ED50) was determined by nonlinear regression (Supplementary Figure S1),
with values included in Table 1.
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Figure 4. DPPH radical scavenging activity of plant extracts. The ability of plant extracts across a
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3.3. Assessment of Plan Extract Neuronal Toxicity
Plant extracts were applied to cultured neuronal (SH-SY5Y) cells over a concen ration range
of 0.16–2.5 mg/mL to assess neurotoxicity. Toxicity of plant extracts was concentration dependent
(Figure 5). At the lowest concentrations applied to cells (0.16 mg/mL) the majority of plant extracts
were nontoxic, with no significant reduction in cell viability (Figure 5). From i hibitor-response curves
of cell viability (Supplementary Figure S3), IC50 concentrations were calculated (Table 1). Toxicity
to neuronal cells was in the order E. globulus > L. inermis > C. reticulata > O. basilicum >M. spicata >
B. ceiba > C. limon. Eucalyptus plant extract was the most toxic (lowest IC 0) and reduced cell viability
by 11.5% at the lowest concentration examined (0.16 mg/mL). In contrast, the pure drug, galantamine,
only induced significant toxicity to neuronal cells (reduced viability of 17%) from a concentration of
1.25 mg/mL. The inhibitor-response curve for galantamine toxicity approached 50% at the highest
concentration examined (2.5 mg/mL), with a predicted IC50 of 3.53 mg/mL (12.2 mM) (refer to Table 1).
3.4. Assessment of Associations between Cholinesterase Inhibition, Radical Scavenging, and Cell Toxicity
To establish if there were any correlations between the studied parameters, a Spearman rank-order
correlation coefficient analysis was performed to examine the relationship between AChE and
BuChE inhibitory potency (Figure 6A), DPPH radical scavenging ability and cholinesterase inhibition
(Figure 6B,C), cell viability and cholinesterase inhibition (Figure 6D,E), and cell viability and DPPH
radical scavenging ability (Figure 6F). There was a positive and significant correlation between potency
of plant extracts to inhibit AChE and BuChE (Figure 6A). Radical scavenging ability was negatively
correlated with either acetyl- or butyryl-cholinesterase inhibitory potency, although not significantly
(Figure 6B,C). Cell viability (measured as MTT assays) was positively correlated with AChE inhibitory
potency and negatively correlated with BuChE inhibitory potency (Figure 6D,E). Cell viability was
positively correlated with radical scavenging potency, but not significantly (Figure 6F).
3.5. Liquid-Chromatography Mass-Spectrometry (LC-MS)
Chemical analyses of the plant extracts were performed using LC-MS/MS, using separation
conditions optimized for Moringa oleifera [43,44]. This revealed several molecular masses present
within all plant extracts, such as rutin (quercetin-3-O-rutinoside) and kaempferol 3-O-glucoside,
as well as others, including 3-caffeoylquinic acid, only present within the two most powerful
cholinesterase-inhibiting plant extracts: L. inermis and E. globulus (refer to Table 2).
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Putative Identification M. oleifera * C. lemon B. ceiba L. inermis E. globulus O. basilicum C. reticulata M. spicata
1 665 C24H42O21 Cellotetraose x 665.17 x x x x 665.17 x
3 341 C12H22O11 Sucrose 341.11 341.11 341.11 341.10 341.09 341.11 341.09 x
4 503 C18H32O16 Cellotriose 503.15 503.17 503.17 x 503.14 x x 503.14
2 367 C17H20O9 Methyl 4-caffeoylquinate 367.10 367.14 367.16 x x x x x
5 278 C14H17NO5 Niazirin 278.07 x x x x x x x
6 191 C7H12O6 Quinic acid isomer 1 191.06 191.06 191.04 x 191.05 x 191.05 x
10 191 C7H12O6 Quinic acid isomer 2 191.02 x 191.02 x x x x x
7 586 C20H29NO15S2
3-Hydroxy-4-(α-l-rhamnopyranosyloxy)
benzyl glucosinolate 586.09 x x x x x x x
8 570 C20H29NO14S2 Glucomoringin 570.07 x x x x x x x
11 408 C14H19NO9S2 Glucotropaeolin x x x x x x x 408.12
12 612 C22H31NO15S2
Acetyl-4-(α-l-rhamnopyranosyloxy)
benzyl glucosinolate 612.07 x x x x x x x
9 353 C16H18O9 3-Caffeoylquinic acid 353.08 x x 353.08 353.07 x x 353.06
13 609 C27H30O16
Rutin
(quercetin-3-O-rutinoside) 609.14 609.14 609.14 609.14 609.13 609.12 609.14 609.13
14 463 C21H20O12 Quercetin 3-O-glucoside 463.08 x 463.08 463.09 463.07 463.07 x x
15 505 C23H22O13 Quercetin-acetyl-glycoside 505.13 x 505.26 x 505.11 505.11 505.25 x
16 447 C21H20O11 Kaempferol 3-O-glucoside 447.08 447.09 447.09 447.07 447.07 447.07 447.06 447.06
17 489 C23H22O12 Kaempferol-acetyl-glycoside 489.10 x x 489.09 489.08 x 489.07 489.13
* M. oleifera was used as a reference extract for peak generation according to Xu et al. [44]. x denotes that the compound was not detected in that peak fraction.
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3.6. Molecular Docking of Potential ChEIs
The cleaned 3D structures of AChE (PDB ID: 4EY5) and BuChE (PDB ID: 6I0C) were used as virtual
targets for binding by the identified phytochemicals: methyl 4-caffeoylquinate (peak #2), 3-caffeoylquinic
acid (peak #9), rutin (peak #13), quercetin 3-O-glucoside (peak #14), quercetin-acetyl-glycoside (peak #15),
kaempferol 3-O-glucoside (peak #16), and kaempferol-acetyl-glycoside (peak #17) (refer to Table 2).
The potential ChEIs were ranked according to their respective binding affinities to AChE and BuChE.
The 3-caffeoylquinic acid displayed the strongest binding affinity for AChE, and rutin the strongest for
BuChE, with binding energies of−9.2 and−11.0 kcal/mol, respectively (Table 3). All these phytochemicals
displayed relatively strong binding affinities to AChE and BuChE compared to the commercial ChEI,
galantamine (Table 3). Indeed, galantamine was only superior to one of the phytochemicals, quercetin
3-O-glucoside, for binding strength to AChE and to one other phytochemical, 3-caffeoylquinic acid,
for binding to BuChE (Table 3).
For the most potent putative AChE inhibitor, 3-caffeoylquinic acid, modeling of its binding to
AChE was undertaken. Figure 7a represents the binding pose of 3-caffeoylquinic acid looking down
the catalytic gorge of AChE. Figure 7b provides a closer inspection of the binding of 3-caffeoylquinic
acid with the active site residues of AChE, demonstrating the hydrogen bonding between the ligand
and target enzyme.
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Similarly, for the most potent putative BuChE inhibitor, rutin, virtual binding looking down the
gorge of BuChE enzyme was performed (Figure 7c), as well as docking of rutin with the active site
residues of BuChE (Figure 7d).
4. Discussion
Neurodegenerative decline, especially dementia, is a social and economic public health pandemic.
Patients suffering from AD represent the greatest number of dementia cases, and deployment of ChEIs
are the first-line drugs to abate the cholinergic deficit that contributes to impaired cognition [45].
Phytochemicals with ChEI and antioxidant activities may prove beneficial at both treatment and
prophylactic levels. Hence, herein, we scrutinized the ability of leaf extracts from commonly cultivated
plants for their nutraceutical efficacy as anti-cholinesterases and antioxidants and considered their
toxicity to neuronal cells.
All the plant extracts examined displayed both AChE and BuChE inhibitory ability, but with broad
potency: with an efficacy range of 32-fold for inhibition of AChE and 18-fold for BuChE. L. inermis
(Henna) leaf extract was the most potent AChE and BuChE inhibitor: with IC50 values of 0.33 and
0.41 mg/mL, respectively. Henna (also commonly known as Mhendi) leaves have historically been
utilized as a stain and dye, but a comprehensive range of pharmacologically active phytochemicals
with desirable health benefits have been reported for leaves and other plant parts [31–34]. This includes
the ability to inhibit AChE: An aqueous leaf extract displayed approximately half of the potency of
the methanolic extract reported herein (IC50 = 0.749 mg/mL) [46] and other methanolic extracts with
relatively weak activity have been described, but without a determination of an IC50 [47]. Hence, to
date, our results appear to be the first determination of an IC50 for a methanolic extract from Henna.
Furthermore, this is the first report of BuChE inhibitory activity from Henna leaf extract and, moreover,
with comparable inhibitory potency to that against AChE.
The biological roles of BuChE have not been fully delineated. Serum BuChE activity has functional
effects upon drug detoxification [48]. BuChE activity also influences lipid metabolism and affects
appetite through modification of ghrelin [49,50]. BChE-deficient mice do not display signs of ill
health and, similarly, humans devoid of active BChE activity have no reduction in longevity [51,52].
Nevertheless, BuChE is able to substitute for AChE, with AChE mice viable [53]. Furthermore, in AD,
BuChE levels increase, presumably to compensate for dwindling ACh functionality [23,54,55]. Hence,
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there may be additional benefit to the development and utilization of dual transient inhibitors of both
cholinesterases to prolong cholinergic signaling [26,56]. For Henna, it is noteworthy that nootropic
benefits have already been reported in vivo [57]. So, further development of Henna extracts could
provide suitable AD-modifying agents.
For the Henna methanolic leaf extract, we also confirmed the presence of antioxidants using a
free radical scavenging spectrophotometric assay. This technique employs the commercially available
1,1-diphenyl-2-picrylhydrazyl free radical (DPPH•), which displays a characterized UV-visible spectrum
with absorbance maxima at approximately 515 nm in methanol. The provision of an antioxidant,
such as a polyphenol, results in a decrease of absorbance that is proportional to the concentration and
antioxidant activity of the compound itself [58,59]. In keeping with our results, other independent
studies have similarly highlighted the presence of a range of Henna phytochemicals able to act as
antioxidants [46,60].
E. globulus (Eucalyptus) was the next most potent inhibitor of both cholinesterases. Specific
reports of anti-AChE or anti-BuChE activities from extracts of E. globulus are absent in the literature.
However, anti-AChE activity has been demonstrated for E. globulus essential oil both in vitro [61]
and in vivo [62]. Essential oils differ from the solvent extracts utilized for our study, since they are
generated primarily through hydrodistillation and via steam or dry distillation processes. Nevertheless,
it is pertinent to consider that certain essential oils are a source of agents with potential beneficial
effects on cognition [63], responses that could, in part, reflect phytochemicals capable of modifying
cholinesterase activities.
For the plants examined, E. globulus displayed the best antioxidant potency. This ability to provide
useful antioxidant and free radical scavenging was also observed for a water extract from E. globulus
leaves, with an IC50 for DPPH of 12 µg/mL, in keeping with our data [64]. This water extract was
also able to scavenge free radicals including those from reactive oxygen species (ROS) and reactive
nitrogen species (RNS), properties proposed to align with the plant’s therapeutic activities [64]. Notable
antioxidant properties from Eucalyptus leaf extracts (as a food additive) [65] and essential oils [66]
have also been reported.
The two citrus fruits, C. reticulata and then C. limon, were the next most powerful inhibitors of both
AChE and BuChE. To our knowledge, our results constitute the first report of anti-AChE and anti-BChE
activity for C. reticulata. Other studies have highlighted potent anti-AChE of C. limon [67] that may
relate to the abundance of flavonoids within citrus fruit [68,69]. Furthermore, C. limon essential oils
also contain anti-cholinesterase activities [70] and were recently shown to ameliorate age-associated
cognitive decline in a mouse model of AD [71].
In contrast to their useful anti-cholinesterase activities, both citrus fruit extracts were weak
antioxidants. Likewise, only low to moderate antioxidant properties have been reported for
C. reticulata and C. limon peel essential oils [61,72]. Nevertheless, irrespective of their relatively
weak antioxidant activity, the multitude of phytochemicals from citrus fruits may contribute to their
purported neuroprotective properties [73].
O. basilicum displayed intermediate anti-cholinesterase activity, as well as antioxidant potential.
Our results for anti-AChE potency of a methanolic leaf extract compare well with those from Farag
et al. (2006) [74], with an IC50 calculated at 6.6 mg/mL. To date, we have not encountered any other
published reports of anti-BuChE activity from O. basilicum. The antioxidant properties of basil are
thought to arise, at least in part, from a rich blend of polyphenolic compounds including phenolic
acids and flavonoids [37,38,75,76]. These O. basilicum phytochemicals may also contribute to memory
enhancement and anti-cholinesterase activity [77,78].
A methanolic leaf extract from B. ceiba displayed relatively weak anti-AChE activity, was the
weakest anti-BuChE inhibitor, and had intermediate antioxidant potential. Similarly, a methanolic
extract from B. ceiba flowers had comparable radical scavenging to our data (EC50 = 87 µg/mL) [79].
Other solvent extracts (ethanolic and hexane) from B. ceiba flowers also retain useful anti-AChE
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inhibition and free radical scavenging abilities [80]. These B. ceiba flower extracts and a methanolic leaf
extract have also displayed neuroprotective potential in vivo [81,82].
Our results show that M. spicata was a strong antioxidant but only a weak cholinesterase inhibitor,
although potent AChE inhibition by Mentha essential oils, including M. spicata (IC50 = 0.088 mg/mL),
has been demonstrated [83]. In keeping with our results, M. spicata’s potency as an antioxidant was
also demonstrated for a water and, to a lesser extent, an ethanolic extract (IC50 of 5.7 and 65.2 µg/mL,
respectively), with both extracts only exhibiting moderate anti-AChE activity [84].
This inverse relationship between DPPH radical scavenging and ability to inhibit cholinesterases
exhibited by M. spicata extracts was also confirmed as a collective for the seven plant extracts
(Figure 6B,C), such that stronger antioxidant potential correlated with weaker cholinesterase inhibition,
although this did not reach significance.
The toxicity of the plant extracts to neuroblastoma cells was examined using the universally
utilized MTT assay. This assay relies upon the reduction of MTT to formazan by non-mitochondrial and
mitochondrial oxidoreductase enzymes. The color change produced directly correlates with cellular
metabolic activity and thereby acts as a surrogate of cell viability or proliferation [85,86] and generates
inhibitor-response curves that invariably follow those for other markers of cell viability such as ATP
depletion or lactate dehydrogenase (LDH) release [87,88].
The inhibitor-response curves for the plant extracts revealed a toxicity range of 4.4-fold from the
least toxic, Citrus limon, to the most toxic, Eucalyptus globulus, with all extracts more toxic than the
single drug treatment of galantamine. Nevertheless, although such partially pure extracts displayed
toxicity to neuronal cells, this was at concentrations significantly higher than that for radical scavenging.
Indeed, functional antioxidant activity was at concentrations at least one order of magnitude below
those that induced toxicity, except for the citrus fruit extracts (C limon and C. recticulata). In contrast,
anti-cholinesterase activity of the plant extracts was at concentrations more comparable to those able
to induce neuronal toxicity. The exception was the Henna extract that not only contained the most
potent anti-cholinesterases but was also an active inhibitor at concentrations below those able to
induce toxicity.
Cellular toxicity and cell death can be induced as a consequence of irreversible inhibition of
acetyl-cholinesterase, such as through organophosphate binding, with induction of redox stress [89,90].
By contrast, the current anti-AD medication elicits less toxicity than organophosphate compounds due
to only transient inhibition of cholinesterases [24,25]. Our correlation analyses showed that toxicity
and loss of cell viability was positively correlated to AChE inhibition, but this did not reach significance
(Figure 6D). Cell viability was also negatively correlated with BuChE inhibition, indicating that the
most potent BuChE inhibitors may be well tolerated.
Correlation analysis also demonstrated a significant positive association between AChE inhibition
and BuChE inhibition. Thus, phytochemicals present in the plant extracts could potentially include
desirable dual cholinesterase inhibitors [26] or mixtures of anti-AChE and anti-BuChE agents. It is also
possible that these different plants contain a number of anti-cholinesterases or the same agent(s) but at
differing concentrations.
Lastly, correlation analysis between cell viability and radical scavenging demonstrated a positive
relationship, although this did not reach significance (Figure 6F). A positive correlation suggests that,
at least for some of the plant extracts, higher (desirable) radical scavenging is associated with more
(undesirable) toxicity. Indeed, beneficial antioxidants could suppress elevation of reactive radicals
liberated in response to phytochemical redox stress. Certainly, there is a need to be mindful that some
polyphenols, including certain flavonoids, are cytotoxic in vitro [91] and, if consumed in excess, may
be toxic in vivo [92]. Thus, plant extracts can be double-edged, with a trade-off between provision of
both beneficial and refractory polyphenols.
To investigate further the phytochemical composition of the plant extracts, we performed
LC-MS/MS. This revealed several molecular masses that were present in all the plant extracts,
such as rutin (quercetin-3-O-rutinoside) and kaempferol 3-O-glucoside, as well as others, including
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3-caffeoylquinic acid, only detected within the two most powerful cholinesterase-inhibiting plant
extracts: L. inermis and E. globulus (refer to Table 2). Consistent with our studies, 3-caffeoylquinic
acid was recently demonstrated to exhibit both AChE and BuChE inhibitory capabilities [93,94].
Furthermore, other flavonoids, including rutin, are also capable of inhibiting AChE [95]. Hence,
these plant extracts likely retain a range of ChEIs of polyphenol origin. Furthermore, from an in
silico molecular modeling approach (Table 3 and Figure 7) [96], an assessment of their potency as
ChEIs was undertaken and compared to the current FDA-approved drug, galantamine. However, it
is appreciated that these plant extracts and phytochemicals will require further evaluation of their
therapeutic potential in vivo.
5. Conclusions
In conclusion, we demonstrated that certain commonly harvested plants retain functional and
potentially beneficial dual cholinesterase inhibitors as well as substantive antioxidant properties.
From further purification and characterization of resident phytochemicals that retain beneficial
pharmacology and with reduced adverse drug reactions, suitable agents may be isolated to provide
nutraceuticals able to stave off the cognitive decline experienced with age and by AD patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/11/1556/s1.
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